Literature DB >> 26221648

[Prognostic benefit of postoperative radiotherapy with adjuvant chemotherapy for stage IIIA/N2, pathologic non-small-cell lung cancer].

Carsten Nieder.   

Abstract

Entities:  

Mesh：

Year:  2015        PMID： 26221648     DOI： 10.1007/s00066-015-0835-1

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN： 0179-7158            Impact factor:   3.621


× No keyword cloud information.
  5 in total

1.  Postoperative radiotherapy for pathologic N2 non-small-cell lung cancer treated with adjuvant chemotherapy: a review of the National Cancer Data Base.

Authors:  Cliff G Robinson; Aalok P Patel; Jeffrey D Bradley; Todd DeWees; Saiama N Waqar; Daniel Morgensztern; Maria Q Baggstrom; Ramaswamy Govindan; Jennifer M Bell; Tracey J Guthrie; Graham A Colditz; Traves D Crabtree; Daniel Kreisel; Alexander S Krupnick; G Alexander Patterson; Bryan F Meyers; Varun Puri
Journal:  J Clin Oncol       Date:  2015-02-09       Impact factor: 44.544

2.  Lymph node ratio may predict the benefit of postoperative radiotherapy in non-small-cell lung cancer.

Authors:  Damien Urban; Jair Bar; Benjamin Solomon; David Ball
Journal:  J Thorac Oncol       Date:  2013-07       Impact factor: 15.609

Review 3.  Postoperative radiotherapy for non-small cell lung cancer.

Authors: 
Journal:  Cochrane Database Syst Rev       Date:  2005-04-18

4.  Re-evaluation of the role of postoperative radiotherapy and the impact of radiation dose for non-small-cell lung cancer using the National Cancer Database.

Authors:  Christopher D Corso; Charles E Rutter; Lynn D Wilson; Anthony W Kim; Roy H Decker; Zain A Husain
Journal:  J Thorac Oncol       Date:  2015-01       Impact factor: 15.609

Review 5.  Modern post-operative radiotherapy for stage III non-small cell lung cancer may improve local control and survival: a meta-analysis.

Authors:  Charlotte Billiet; Herbert Decaluwé; Stephanie Peeters; Johan Vansteenkiste; Christophe Dooms; Karin Haustermans; Paul De Leyn; Dirk De Ruysscher
Journal:  Radiother Oncol       Date:  2013-10-04       Impact factor: 6.280
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.